spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  mitoxantrone 

 HSMN NewsFeed - 28 Oct 2013
Lorus Therapeutics Appoints New Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Jul 2011
XGEVA(R) (Denosumab) Granted Marketing Authorization in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 May 2011
Amgen Receives CHMP Positive Opinion for XGEVA (Denosumab) in the European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Oct 2010
Phase III Data Showing Improved Survival With Jevtana(R) (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Sep 2009
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2008
Spectrum Pharmaceuticals Announces Sale of Injectable Generic Drugs to Sagent Pharmaceuticals, Inc.
Biopharmaceuticals Generics
 HSMN NewsFeed - 10 Apr 2008
COPAXONE(R) Significantly Reduced Annual Relapse Rates and Stabilized Disease Progression in Relapsing Remitting Multiple Sclerosis Patients Failing Interferon Treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 Mar 2008
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Jul 2007
Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 25 Jul 2007
Cell Therapeutics, Inc. (CTI) Announces Agreement to Acquire SMi; Gains Global Rights to Brostallicin, in a New Class of Cancer Killing Agents
Biopharmaceuticals Mergers & Acquisitions Oncology
 HSMN NewsFeed - 4 Jun 2007
Updated Study Results Reinforce Survival Benefit of Taxotere(R) (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 May 2007
Treatment with COPAXONE(R) Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 4 May 2007
COPAXONE(R) Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Apr 2007
Novacea Acquires Worldwide Development and Commercialization Rights for Its Oncology Candidate AQ4N
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 30 Jan 2007
YM BioSciences announces termination of the tesmilifene Phase III pivotal trial in advanced breast cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jan 2007
European Association of Nuclear Medicine Journal Article Reports New Data Regarding Administration of QUADRAMET(R) with Chemotherapy in Hormone Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jan 2007
Merck Serono Has Initiated the ONWARD Study to Evaluate Oral Cladribine as Add-on Treatment for Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Jan 2007
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 Dec 2006
Serono Announces Initiation of the Reflex Trial to Evaluate New Formulation of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Dec 2006
'Impressive' Complete Remission and 'Durable' Survival Data in Relapsed Indolent NHL Patients Identifies New Potential Registration Trial for Pixantrone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Sep 2006
Very Active Multiple Sclerosis Patients Benefited from COPAXONE(R) Treatment Following Short-Term Induction with Mitoxantrone
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Sep 2006
Study Showed Significant and Sustained Efficacy Of COPAXONE(R) Alone Following Short-Term Combination Therapy With IV Steroids in Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
One-year Data From Phase III Trial Show That New Formulation of Rebif(r) Offers Substantial Improvement in Tolerability and Immunogenicity Profiles
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Jul 2006
European Commission Approves Revision of Therapeutic Indication for Rebif(R)
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 31 May 2006
NeoRx Corporation (Poniard Pharmaceuticals) Announces Treatment of First Patient With Picoplatin in Phase 1/2 Front-Line Prostate Cancer Trial
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 64

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 64 additional stories matching:
mitoxantrone
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.